Detected ·
Soufflé Therapeutics
$135M—
Soufflé Therapeutics closed an oversubscribed $135M Series B led by Juvia Group, with participation from TCGX, BB Biotech, Fidelity, ARCH Venture Partners, Bessemer, Amgen, and others, to advance its REMEDY™ cell-specific delivery platform and pipeline programs.
- Website
- www.souffletx.com
- Amount
- $135 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-10-14 04:03:35 UTC
- Signal ID
- 28366819-504f-4605-8577-2f743bdcc55a
As the API returns it
{
"id": "28366819-504f-4605-8577-2f743bdcc55a",
"created_at": "2026-10-14T04:03:35.601671Z",
"company_name": "Soufflé Therapeutics",
"company_website_url": "www.souffletx.com",
"company_linkedin_url": "https://www.linkedin.com/company/souffletherapeutics",
"event_type": "funding",
"funding_amount": 135000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Soufflé Therapeutics closed an oversubscribed $135M Series B led by Juvia Group, with participation from TCGX, BB Biotech, Fidelity, ARCH Venture Partners, Bessemer, Amgen, and others, to advance its REMEDY™ cell-specific delivery platform and pipeline programs.*"
}